Marker Therapeutics, Inc.(MRKR)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Marker Therapeutics, Inc. (MRKR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MRKR at 21.3/100 on a 32-signal composite quality model, placing it at rank #2,768 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of MRKR by reported 13-F value include NEA Management Company, Blue Owl Capital, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MRKR trades on the Nasdaq exchange and files with the SEC under CIK 1094038. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MRKR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Marker Therapeutics, Inc. directly from SEC EDGAR.
AI Quality Score
21.3/100
AI Rank
#2,768
Net Income
$-1.8M
MRKR key financials by period
Marker Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$3.5M
$-12.2M
—
FY 2024
10-K
$6.6M
$-10.7M
-168.7%
FY 2023
10-K
$3.3M
$-8.2M
—
FY 2022
10-K
$3.5M
$-29.9M
—
FY 2020
10-K
$500.0K
$-28.7M
—
FY 2019
10-K
$213.2K
$-21.4M
—
Institutions holding MRKR
Institutional investors reporting a position in Marker Therapeutics, Inc. on SEC Form 13F.
